Bio-Techne (ISIN US09073M1045) has its next quarterly reporting date scheduled for November 4, 2026, according to MarketBeat.

Shares of Charles River Laboratories International Inc. rose 5.14% to $315.45 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index rising ...

Oct 19 (Reuters) - German drugmaker Merck KGaA said on Monday it would acquire UK-based Silence Therapeutics in an all-cash ...

US-listed shares soared Monday after the UK-based biotechnology company agreed to be acquired by Germany's Merck KGaA in a cash deal for an equity value of about $1.3 billion. Silence Therapeutics is ...

Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash deal worth about $1.3 billion in equity value, paying $20.00 per ADS -- a ...

Merck KGaA announced its acquisition of Silence Therapeutics for $1.3 billion, enhancing its gene silencing strategies and ...

The German pharmaceutical and technology group Merck is expanding its rare disease business with the acquisition of the British biotech firm Silence Therapeutics, the DAX-listed company said on Monday ...

Merck agrees to acquire Silence Therapeutics for $20 per ADS in a $1.3 billion equity deal, adding Divesiran to its rare ...

Discover Seeking Alpha's Undercovered Stocks: 12 overlooked stocks from the past week to spark new investment ideas.

TRex Bio, Inc. develops immunoregulatory biologics for autoimmune and inflammatory diseases in United States and Internationally. The company operates the Deep Biology Platform, a drug discovery and ...

Merck KGaA (XTRA:MRK) is back in focus after Silence Therapeutics agreed to a proposed all-cash acquisition worth about $1.3 ...